Evidence map›Paper›PMID 21642934›Full record

ReviewMolecules (Basel, Switzerland)2011

Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment.

Purusotam Basnet, Natasa Skalko-Basnet

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecules (Basel, Switzerland), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04353310 (Evaluating the Effects of Curcumin in Moderate to Severe Asthmatics), which is not on this map. Cited by 237 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
237citing papers in PubMed, 3 pooled it
13.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04353310 phase2withdrawnnot on this mapstarted 2021, after this paper: background citation

Evaluating the Effects of Curcumin in Moderate to Severe Asthmatics

TypeinterventionalSponsorLoma Linda UniversityRan2021 to 2021Enrolled0ConditionsAsthmaArmsCurcumin, Placebo
3 · Its place in the literature

Who cites it

237 citing papers in PubMed, 3 syntheses or guidelines pooled it, 735 citations in OpenAlex.

  1. Pooled it
  2. Frontiers in oncology · 2021
    Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Evaluation of the Impact of Different Doses ofBioMed research international · 2021
    Trial
  7. Trial
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

177 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Purusotam BasnetDrug Transport and Delivery Research Group, Department of Pharmacy, University of Tromsø, Tromsø N-9037, Norway. purusotam.basnet@uit.no
Natasa Skalko-Basnet
UiT The Arctic University of Norway · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxidative damage and inflammation have been pointed out in preclinical studies as the root cause of cancer and other chronic diseases such as diabetes, hypertension, Alzheimer's disease, etc. Epidemiological and clinical studies have suggested that cancer could be prevented or significantly reduced by treatment with anti-oxidant and anti-inflammatory drugs, therefore, curcumin, a principal component of turmeric (a curry spice) showing strong anti-oxidant and anti-inflammatory activities, might be a potential candidate for the prevention and/or treatment of cancer and other chronic diseases. However, curcumin, a highly pleiotropic molecule with an excellent safety profile targeting multiple diseases with strong evidence on the molecular level, could not achieve its optimum therapeutic outcome in past clinical trials, largely due to its low solubility and poor bioavailability. Curcumin can be developed as a therapeutic drug through improvement in formulation properties or delivery systems, enabling its enhanced absorption and cellular uptake. This review mainly focuses on the anti-inflammatory potential of curcumin and recent developments in dosage form and nanoparticulate delivery systems with the possibilities of therapeutic application of curcumin for the prevention and/or treatment of cancer.

Indexed as

PhytotherapyAnimalsAnti-Inflammatory AgentsAntineoplastic AgentsBiological AvailabilityChemistry, PharmaceuticalCurcumaCurcuminDrug Delivery SystemsHumansInflammationMolecular Targeted TherapyNeoplasmsPlant ExtractsSignal TransductionAnti-Inflammatory AgentsAntineoplastic AgentsCurcuminPlant Extractsturmeric extract

Identifiers

PMID21642934
PMCPMC6264403
OpenAlexW2102192655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.